Skip to main content
    R

    Rocket Pharmaceuticals Inc (RCKT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.16
    -0.14 (-6.09%)

    Market Cap: $256.82M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Rocket Pharmaceuticals Inc (RCKT) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Rocket Pharmaceuticals are ProQR Therapeutics BV (PRQR), Korro Bio (KRRO) and Arcturus Therapeutics Holdings (ARCT). By market cap, Rocket Pharmaceuticals ranks 8th of the 13 companies on this page; Gyre Therapeutics (GYRE) is the largest at $471.74M.

    Peer Comparison

    RCKT's ROIC of -2.3% is above the peer median of -82.8%, and its revenue growth of 0.0% is below the median of 0.3%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Rocket Pharmaceuticals (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    ProQR Therapeutics BV (PRQR)$199.28MN/A6.1x-228.2%N/A120.4%0.00%
    Korro Bio, Inc. (KRRO)$186.81MN/A175.8x0.0%-82.8%-43.1%0.00%
    Arcturus Therapeutics Holdings Inc (ARCT)$240.96MN/A7.7x-285.9%N/A6.7%0.00%
    Rezolute Inc (RZLT)$353.54MN/AN/A0.0%N/A0.0%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Keros Therapeutics Inc (KROS)$202.13MN/A4.9x-151.4%N/A180.5%0.00%
    Opus Genetics, Inc. (IRD)$384.68MN/A52.0x0.0%-145.1%-63.1%0.00%
    Precision BioSciences Inc (DTIL)$288.76MN/A4.4x-85.6%-38.3%37272.0%0.00%
    Gyre Therapeutics Inc. (GYRE)$471.74MN/A3.8x-22.7%N/A0.7%0.00%
    Larimar Therapeutics Inc (LRMR)$313.73MN/AN/A0.0%N/A0.0%0.00%
    Prothena Corporation plc (PRTA)$419.01MN/A7.8x-45.4%N/A-74.3%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Peer median$282.04MN/A7.7x-34.0%-82.8%0.3%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Rocket Pharmaceuticals, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    ProQR Therapeutics BV (PRQR)
    ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders.
    PRQR competitors
    Korro Bio, Inc. (KRRO)
    Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare...
    KRRO competitors
    Arcturus Therapeutics Holdings Inc (ARCT)
    Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases.
    ARCT competitors
    Rezolute Inc (RZLT)
    Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States.
    RZLT competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Keros Therapeutics Inc (KROS)
    Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery...
    KROS competitors
    Opus Genetics, Inc. (IRD)
    Opus Genetics, Inc. (IRD) is a pioneering biotechnology company dedicated to advancing gene therapies for rare retinal diseases that affect vision.
    IRD competitors
    Precision BioSciences Inc (DTIL)
    Precision BioSciences, Inc., a genome editing company, develops therapeutic products in the United States.
    DTIL competitors
    Gyre Therapeutics Inc. (GYRE)
    Gyre Therapeutics Inc. is a pioneering biopharmaceutical company at the forefront of developing advanced therapies for rare and complex diseases.
    GYRE competitors
    Larimar Therapeutics Inc (LRMR)
    Larimar Therapeutics, Inc., a clinical-stage biotechnology company, is focused on developing treatments for rare diseases.
    LRMR competitors
    Prothena Corporation plc (PRTA)
    Prothena Corporation plc, an advanced stage clinical company, is focused on the discovery and development of new therapies for life-threatening diseases...
    PRTA competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors

    Frequently Asked Questions About RCKT

    Who are Rocket Pharmaceuticals' main competitors?

    The companies most similar to Rocket Pharmaceuticals include ProQR Therapeutics BV (PRQR), Korro Bio (KRRO), Arcturus Therapeutics Holdings (ARCT), Rezolute (RZLT) and Protara Therapeutics (TARA), listed from the closest match.

    Who is Rocket Pharmaceuticals' biggest competitor?

    Gyre Therapeutics (GYRE) is the largest of the similar companies at $471.74M; ProQR Therapeutics BV (PRQR) is the closest match by business profile, size, sector and industry.

    How does RCKT stock compare with its competitors?

    RCKT's net margin is 0.0% against a peer median of -34.0%.

    Which of Rocket Pharmaceuticals' competitors pays a higher dividend?

    Rocket Pharmaceuticals pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Rocket Pharmaceuticals bigger than its competitors?

    No. Rocket Pharmaceuticals is 8th by market cap among the 13 companies on this page; the largest is Gyre Therapeutics (GYRE) at $471.74M.